Skip to main content
    V

    Vor Biopharma Inc (VOR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $18.97
    -0.45 (-2.32%)

    Market Cap: $1.19B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Vor Biopharma Inc (VOR) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Vor Biopharma (VOR) to earn -$6.67 per share in the fiscal year ending Dec 31, 2026. Of 10 analysts, 9 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 10 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 90% of the ratings.

    RatingAnalystsShare
    Strong Buy110.0%
    Buy880.0%
    Hold110.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    10

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss.

    Fiscal year ending Dec 31, 2026
    -$6.67
    EPS consensus
    Fiscal year ending Dec 31, 2027
    -$3.34
    EPS consensus
    Next report
    Mar 29, 2027
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analysts
    Dec 31, 2026-$6.67-$8.64 to -$3.404
    Dec 31, 2027-$3.34-$3.90 to -$2.534

    Quarterly Estimates

    The EPS consensus falls from -$0.95 for the quarter ending Dec 31, 2026 to -$0.99 for the quarter ending Mar 31, 2027.

    EPS range

    Quarter endingEPS consensusEPS rangeEPS analysts
    Dec 31, 2026-$0.95-$1.17 to -$0.7811
    Mar 31, 2027-$0.99-$0.99 to -$0.991

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 2 upward and 1 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202601
    Fiscal year ending Dec 31, 202720
    Quarter ending Mar 31, 202700

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$6.90.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$6.67-$6.89-$6.53-$6.53-$6.90N/A
    Fiscal year ending Dec 31, 2027-$3.34-$3.67-$3.82-$3.81-$3.74N/A

    Frequently Asked Questions About VOR

    What is the VOR stock forecast?

    Consensus analyst estimates put Vor Biopharma's EPS at -$6.67 for the fiscal year ending Dec 31, 2026. The consensus rating from 10 analysts is Buy.

    How do analysts rate VOR stock?

    Of 10 analysts covering Vor Biopharma, 1 rates it Strong Buy, 8 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from VOR next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$6.67, with estimates from -$8.64 to -$3.40 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$3.34, with estimates from -$3.90 to -$2.53 from 4 analysts.

    How many analysts cover VOR?

    10 analysts rate Vor Biopharma stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.